Business Summary: Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Mabion SA revenues increased 68% to PLN4.6M. Net loss decreased 36% to PLN9.7M. Revenues reflect Sale of Products increase of 51% to PLN3.8M, Sales of Materials increase of 22% to PLN261K. Lower net loss reflects General/Admin. Expense decrease of 21% to PLN6.6M (expense), Foreign Exchange Loss decrease of 86% to PLN178K (expense), Int exp on Financial Lease Liabilities decrease of 50% to PLN109K (expense).